Marianne De Backer talks about joining Vir Biotechnology and shares her vision for the future

Alto Neuroscience's CEO on why MDD data at #ACNP2023 may validate its precision medicine approach

BridgeBio's Neil Kumar reviews #AHA23 data and the company's pipeline and finances

Checking in with Cytokinetics ahead of the SEQUOIA-HCM P3 study result due in December

Carisma's CEO discusses their Moderna-partnered CAR-M preclinical late breaker at #SITC23

Ambrx's CEO & CSO discuss the ADC space and recent #ESMO23 data

Kura Oncology's CEO gives an update on Q3 earnings day

The Co-CEO of Renibus Therapeutics shares a company's perspective of the N. Texas biotech ecosystem

A deep dive into the oncology target PRMT5 with the CEO of Tango Therapeutics

Brushing up on the science of obesity with Rhythm Pharmaceuticals’ CEO

Monte Rosa's CEO discusses yesterday's data for MRT-2359 in MYC-driven solid tumors

Amylyx's Co-CEOs comment on Friday's European CHMP decision on their ALS therapy

The CEO of eGenesis elaborates on today's Nature paper using pig kidneys for transplantation in NHPs

The Head of Bayer in the US on pharma and a new $250M cell Tx facility in Berkeley, CA. #HLTH2023

Analyzing Nanobiotix's P1 Head & Neck data for the radioenhancer NBTXR3 from #ASTRO2023

Delfi Diagnostics' team on launching the FirstLook Lung cancer blood screening test at #HLTH2023

Harbinger Health’s Steve Hahn on the science of early cancer Dx after raising a $140M Series B

Learning about molecular glues from the CEO of Orionis Biosciences following a recent Genentech deal

Rome Therapeutics’ CEO on the science of the 'Dark Genome' and last week’s $72M Series B extension

Generate Biomedicines' Mike Nally on Thursday's $273M Series C and computational drug development